Primitive Neuroectodermal Tumor — Trials

Primitive Neuroectodermal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 146
Recruiting: 80
Ph III recruiting: 8
Growth YoY: −33.3%
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 201–250 of 266 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00098865	Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma	completed	Phase 2	15	Dana-Farber Cancer InstituteOTHER	1	Oct 7, 2014	clinicaltrials
NCT00357500	Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer	completed	Phase 2	101	Dana-Farber Cancer InstituteOTHER	1	Oct 1, 2014	clinicaltrials